These assignments were based on areas of particular expertise of writing committee members. All recommendations were fully reviewed and discussed among the full com- mittee to allow for diverse perspectives and consider- ations for this guideline. Recommendations were then voted upon, with a modified Delphi process used to reach consensus. 1.2. Organization of the Writing Committee The writing committee consisted of clinicians, cardi- ologists, health services researchers, epidemiologists, internists, nurses, and a lay representative. The writing committee included representatives from the ACC and AHA. Appendix 2 of the present document lists writing committee members relevant RWI. For the purposes of full transparency, the writing committee members com- prehensive disclosure information is available online. 1.3. Document Review and Approval This document was reviewed by 5 official reviewers nominated by the ACC and AHA (1 reviewer from the ACC/AHA Task Force for Practice Guidelines, 2 review- ers from the AHA, and 2 reviewers from the ACC); 3 reviewers on behalf of the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Society for Nutrition, and the American So- ciety of Preventive Medicine; and 23 individual con- tent reviewers. Reviewers RWI information was dis- tributed to the writing committee and is published in this document (Appendix 3). This document was ap- proved for publication by the governing bodies of the ACC and AHA. CLINICAL STATEMENTS AND GUIDELINES 1.4. Scope of the Guideline This guideline is intended to be a resource for the clinical and public health practice communities. It addresses the primary prevention of CVD in adults ( 18 years of age), focused on outcomes of ASCVD (ie, acute coronary syndromes, MI, stable or unstable angina, arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of ath- erosclerotic origin), as well as heart failure and atrial fibrillation. 